LAMY

LAMY (transitioning to Exousia Bio, Inc.) is a clinical-stage biotechnology company focused on developing exosome-based therapies for oncology and infectious diseases. The company utilizes a proprietary platform for the manufacturing and loading of mammalian and plant-derived exosomes with therapeutic payloads, including drugs and DNA. Its lead program, an exosome-based therapy for glioblastoma multiforme (GBM), has received FDA Orphan Drug Designation following successful preclinical in-vivo studies. LAMY's technology also targets cancer stem cells to address disease recurrence and metastasis in indications such as pancreatic cancer. In addition to its core biotech division, the company maintains interests in cosmeceutical and nutraceutical applications of plant-based exosomes.